NCT06335355尚未招募2 期
A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations
Shanghai Shengdi Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 401 人开始时间: 2024年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 401
- 试验地点
- 1
- 主要终点
- Investigator-assessed Objective Response Rate (Phase One)
研究概览
简要总结
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant voluntarily joins this clinical research study, understands the research procedures, and is capable of providing written informed consent by signing the Informed Consent Form.
- •At the time of signing the Informed Consent Form, participants must be between the ages of 18 and 75 years old (inclusive), with no gender restrictions.
- •Diagnosed with advanced or metastatic non-squamous NSCLC (non-small cell lung cancer) confirmed by histology or cytology.
- •At least one measurable tumor lesion outside the central nervous system that meets the RECIST v1.1guidelines .
- •The participant is expected to have a life expectancy of at least 12 weeks.
- •Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed.
- •The participant must have adequate bone marrow and organ function.
排除标准
- •Pathologically or cytologically confirmed mixed Small Cell Lung Cancer (SCLC), sarcomatoid carcinoma, or neuroendocrine carcinoma.
- •Subjects with untreated or active Central Nervous System (CNS) metastases, those with a history of leptomeningeal metastasis, or those currently presenting with leptomeningeal metastasis.
- •Subjects with spinal cord compression that has not been radically treated by surgery and/or radiotherapy.
- •Subjects with inadequately controlled pain related to their tumor(s).
- •Subjects with a history of or concurrent other malignancies, except for basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, in situ cervical cancer, localized prostate cancer, ductal carcinoma in situ following mastectomy (allowing for hormonal treatment for non-metastatic prostate or breast cancer), and papillary thyroid cancer which have achieved complete remission for at least 5 years prior to screening and do not require or are not expected to require further treatment during the study period.
- •Subjects who have received Chinese herbal anti-tumor treatment within 2 weeks prior to initiating the study treatment.
- •Subjects whose toxicities and/or complications from previous interventions have not resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE 5.0) Grade ≤
- •Subjects participating in another clinical study or whose initiation of study treatment is less than 4 weeks since the end of the last clinical study (last dose administration), or less than five half-lives of that study drug, whichever is shorter.
- •Subjects who have received systemic immunostimulant treatment within 4 weeks prior to starting the study treatment.
- •Subjects who have received systemic immunosuppressive treatment within 2 weeks prior to starting the study treatment.
- •Subjects with any active, known, or suspected autoimmune disease.
- •Subjects with severe heart disease.
- •Subjects who have experienced arterial or venous thrombotic events within 3 months prior to starting the study treatment.
- •Subjects with active syphilis infection.
- •Subjects who have had a severe infection within 4 weeks prior to starting the study treatment.
- •Subjects who have previously undergone or are planning to undergo allogeneic hematopoietic stem cell transplantation or organ transplantation.
- •Subjects with a history of severe hypersensitivity reactions to other monoclonal antibodies.
- •Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- •Subjects with a history of substance abuse of psychoactive drugs, alcoholism, or drug addiction.
- •Subjects whom the investigator believes have any medical condition (such as pulmonary, metabolic, endocrine, or neurological diseases, congenital disorders, etc.), psychiatric conditions, or social circumstances that could potentially interfere with the subject's rights, safety, health, or ability to provide informed consent, cooperate, and participate in the study, or interfere with the assessment of the investigational drug, interpretation of subject safety data, or study results.
研究组 & 干预措施
Treatment group C
Active Comparator
干预措施: Adebrelimab + Pemetrexed + Carboplatin (Drug)
Treatment group A
Experimental
干预措施: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin (Drug)
Treatment group B
Active Comparator
干预措施: Camrelizumab + Pemetrexed + Carboplatin (Drug)
结局指标
主要结局
Investigator-assessed Objective Response Rate (Phase One)
时间窗: about 3 years
Overall Survival (Phase Two)
时间窗: about 3.5 years
次要结局
- The incidence and severity of Adverse Events (AEs) (Phases One and Two)(about 4.5 years)
- Duration of Response (DoR) based on Investigator Assessment (Phases One and Two)(about 6.5 years)
- Disease Control Rate (DCR) based on Investigator Assessment (Phases One and Two)(about 6.5 years)
- Progression-Free Survival (PFS) based on Investigator Assessment (Phases One and Two)(about 6.5 years)
- Overall Survival (OS) (Phase One)(about 3.5 years)
- Objective Response Rate (ORR) based on Investigator Assessment (Phase Two)(about 4.5 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.Esophageal CancerNCT06464614The First Affiliated Hospital of Henan University of Science and Technology54
招募中
2 期
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLCNon Small Cell Lung CancerNCT06424899Zeng Jian92
尚未招募
2 期
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCEsophageal Squamous Cell CarcinomaNCT06508229Harbin Medical University65
进行中（未招募）
2 期
Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation PneumonitisUnresectable Locally Advanced Non-small Cell Lung CancerNCT06700421Wei Zhou32
招募中
2 期
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)Adebrelimab (SHR-1316)XELOXGC/GEJCNCT06506292Tianjin Medical University Cancer Institute and Hospital25